UNSPSC 51131650: Rivaroxaban

This classification denotes an anticoagulant agent with the molecular formula C19H18ClN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9NDF7JZ4M3, chemically known as 5-chloro-n-(((5s)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide but generally known as rivaroxaban, which bears US NIH Compound Identifier 6433119. European Medicines Agency schedules Rivaroxaban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29263.

UNSPSC 51131650 Rivaroxaban is a Commodity code that nominally identifies a specific anticoagulant pharmaceutical product; however, the recent state and local procurement activity tagged under this code does not reflect pharmaceutical procurement. Instead, the only recent opportunity on record is Sourcewell RFP #061626, issued May 12, 2026 with response due June 16, 2026, which solicits law enforcement equipment — a scope wholly unrelated to rivaroxaban or pharmaceutical products. This mismatch suggests either a data-entry or categorization error in how the opportunity was tagged, or that the code shows little genuine pharmaceutical procurement activity in the state and local market at present.

The Sourcewell procurement is a cooperative purchasing vehicle administered by the State of Minnesota on behalf of multiple Washington counties (Franklin, Grant, Grays Harbor, Chelan, and Yakima) and numerous other public entities nationwide and in Canada, with responses submitted through the Sourcewell Procurement Portal by June 16, 2026 at 3:30 p.m. Central Time. Absent evidence of substantive recent state and local opportunities genuinely soliciting rivaroxaban or related pharmaceutical products under this code, the code shows no actionable pharmaceutical procurement activity to evaluate.